Skip to main content
BriaCell Therapeutics Corp. logo

BriaCell Therapeutics Corp. — Investor Relations & Filings

Ticker · BCTX ISIN · CA1079303071 TSX Manufacturing
Open in API
Filings indexed 305 across all filing types
Latest filing 2026-04-21 Regulatory Filings
Country CA Canada
Listing TSX BCTX

About BriaCell Therapeutics Corp.

https://briacell.com/

BriaCell Therapeutics Corp. is a clinical-stage immuno-oncology company developing targeted cellular immunotherapies using a patented whole-cell vaccine technology designed to activate the patient's immune system against tumor cells. The lead candidate, Bria-IMT , is an off-the-shelf, cell-based immunotherapy currently in a pivotal Phase 3 study for advanced metastatic breast cancer (MBC). Bria-IMT has shown clinical efficacy, including unprecedented survival benefit in heavily pre-treated MBC patients resistant to checkpoint inhibitors and antibody-drug conjugates, and those with CNS metastases. BriaCell's next-generation platform, Bria-OTS /Bria-OTS+ , offers personalized, off-the-shelf treatment engineered to match over 99% of patients' HLA types. This platform is being evaluated in Phase 1/2 trials for breast, prostate, lung cancer, and melanoma, aiming to provide rapid and cost-effective personalized cancer care.

Recent filings

Filing Released Lang Actions
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the presentation of preclinical data for BriaCell's Bria-OTS+ platform at the 2026 American Association for Cancer Research (AACR) Annual Meeting. It contains no financial data, no regulatory filings, no voting results, no management changes, no earnings or interim reports, and no detailed investor presentations. It is a scientific and clinical update rather than a financial or regulatory document. The document is about presenting research data at a conference, which is not covered by the specific categories related to financial or corporate filings. Therefore, the best fit is Regulatory Filings (RNS) as a general announcement that does not fit other categories.
2026-04-21 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release announcing the presentation of clinical data at the 2026 AACR Annual Meeting. It details Phase 3 and Phase 2 clinical trial results, including quality of life outcomes and biomarker data, but does not contain full financial statements or comprehensive financial performance data. It is not a transcript of a call, nor an official regulatory filing or report. The document is primarily an announcement of clinical research presentations and data highlights rather than a formal report or filing. Therefore, it fits best under the category of Regulatory Filings (RNS) as a general announcement that does not fit other specific categories.
2026-04-20 English
News release - English.pdf
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing the presentation of clinical trial posters at the 2026 AACR Annual Meeting, including forward‐looking statements and contact details. It is not an earnings release, financial report, or any formal regulatory filing category listed. It does not announce dividends, share transactions, board changes, or an offering. It is a general company news announcement, best fitting the fallback category of Regulatory Filings (RNS).
2026-04-20 English
News release - English.pdf
M&A Activity Classification · 90% confidence The document is a press release announcing the closing of an asset purchase transaction (exclusive license to sCD80), detailing the terms of the purchase agreement, share issuance as consideration, the appointment of a new board chair following the transaction, shareholder approval percentages, and early warning shareholding disclosures. This clearly falls under M&A Activity rather than a regular financial report or earnings release. Hence, it is classified as M&A Activity (TAR).
2026-03-31 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a template and instructional guide for 'Form 45-106F1: Report of Exempt Distribution', which is a standard regulatory filing used in Canadian jurisdictions to report the distribution of securities under prospectus exemptions. Since this document provides the regulatory framework, instructions, and the form structure itself rather than a specific company's financial report or a unique event announcement, it falls under the 'Regulatory Filings' category as a general regulatory document.
2026-02-17 English
News release - English.pdf
Regulatory Filings Classification · 95% confidence The document is a press release issued by BriaCell Therapeutics Corp. regarding clinical trial results (patient imaging and tumor regression). It is not a formal financial report, audit, or regulatory filing, but rather a corporate announcement of clinical progress. In the context of financial document classification, press releases regarding clinical trial updates or product development milestones that do not fit into specific categories like 'Earnings Release' or 'M&A' are classified as 'Regulatory Filings' (RNS) as they serve as general corporate disclosures to the market.
2026-01-28 English

Browse filings by year

7 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.